ClinicalTrials.gg
RecruitingNCT06570629Updated Apr 30, 2025

Addressing Unintentional Leakage When Using Nasal CPAP - Study B

An interventional study of Oronasal CPAP and Nasal CPAP plus Chinstrap in Continuous Positive Airway Pressure, Adverse Effect and Obstructive Sleep Apnea, sponsored by University of Sao Paulo General Hospital. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by University of Sao Paulo General Hospital · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 13 studies in Sleep Apnea, Obstructive by University of Sao Paulo General Hospital — 2 open to participants now, 3 under way, none of them phase 3. Sleep Apnea, Obstructive · University of Sao Paulo General Hospital.

Planned enrollment
5th of 11
50 · median 50
Started
2025
with 1 other
No phase
10 of 13
2 open now
Registered
12th of 13
by date

Among the 13 studies in Sleep Apnea, Obstructive by University of Sao Paulo General Hospital, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, and was the 12th registered.

Sleep Apnea, Obstructive

2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

2 of the 13 studies in Sleep Apnea, Obstructive by University of Sao Paulo General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 313 Sleep Apnea, Obstructive studies recruiting now, 145 (46%) set no upper age limit and 125 (40%) stop at 75 or younger; 53 take children under 18; 65 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Sleep Apnea, Obstructive by University of Sao Paulo General Hospital, or all of them as a file.
02

Study summary

Oral unintentional leak is a common side effect of continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA) treatment. Management of oral unintentional leakage has not been standardized and the effectiveness of potential approaches have not been studied in controlled studies. Higher levels of CPAP are associated with higher leak. In the present study, a sequential approach to control excessive unintentional leak will be tested. In study A, the reduction of therapeutic CPAP level will be tested. In study B, oronasal CPAP will be compared to nasal CPAP with a chinstrap.

Read the detailed description

Study B will consist of a controlled crossover trial to compare unintentional leak during the use of an oronasal mask versus a nasal mask with a chinstrap, among subjects who remain with excessive leak at the end of study A. The order of interventions will be randomized. One of the groups will initially use an oronasal mask for 10 days. A washout period of 7 days under nasal CPAP will follow. After washout, subjects will continue using a nasal mask and will be asked to use a chinstrap for another 10 days. In the other group, the order of interventions will be the opposite.

03

Conditions studied

  • Continuous Positive Airway Pressure
  • Adverse Effect
  • Obstructive Sleep Apnea

Keywords

  • CPAP
  • Excessive leak
  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of moderate and severe obstructive sleep apnea;
  • Use of CPAP with a nasal mask;
  • 95th percentile of unintentional leak from the last 7 days above 24 l/min, or at least 4 sudden drops of leak over one night of nasal CPAP
  • Persistence of excessive leak at the end of Study A.

Exclusion criteria

Exclusion Criteria:

  • Patients who experience unintentional leakage from the mask/accessories.
  • Diagnostic polysomnography examination with a predominance of central apnea;
  • Patients with unstable heart disease, bedridden, neurodegenerative diseases, severe psychiatric disorders and ;
  • Previous surgery for obstructive sleep apnea;
  • Severe nasal obstruction (NOSE questionnaire score equal or greater then 55 points).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Oronasal CPAP

    CPAP with an oronasal mask for 7 days.

    Device: Oronasal CPAP

  • Experimental
    Chinstrap

    CPAP with a nasal mask and a chinstrap for 7 days.

    Device: Nasal CPAP plus Chinstrap

Interventions

  • DeviceOronasal CPAP

    In this crossover trial, subjects will use CPAP with either an oronasal mask or a. nasal mask with a chinstrap for 7 days. The order of each intervention will be randomized.

  • DeviceNasal CPAP plus Chinstrap

    In this crossover trial, subjects will use CPAP with either an oronasal mask or a. nasal mask with a chinstrap for 7 days. The order of each intervention will be randomized.

06

What researchers measure

Primary outcomes

  1. 95th CPAP unintentional leak

    The 95th unintentional leak percentile value will be compared during both interventions

    Time frame: 27 days

Secondary outcomes

  1. CPAP Side-effects questionnaire

    This questionnaire addresses CPAP side-effects including those related to excessive air leak using a visual-analog scale.

    Time frame: 27 days

  2. Residual apnea-hypopnea index (AHI)

    Residual AHI will be compared during both interventions

    Time frame: 27 days

  3. Functional Outcomes of Sleep Questionnaire (FOSQ 10)

    The FOSQ 10 aims to assess the impacts of daytime sleepiness on daily activities. The FOSQ 10 consists of 10 questions comprising 5 items: General productivity, alertness, activity level, social outcomes, and intimate and sexual relationships. Each item generates a score from 1 to 4, and for items with more than one question, the average of the scores is calculated. The overall score is given by multiplying the average of the item scores by 5, obtaining a value from 5 to 20. The higher the score, the better the individual's functional status.

    Time frame: 27 days

  4. Pittsburgh questionnaire

    The Pittsburgh questionnaire assessed sleep quality over the past month. The questionnaire consists of 19 self-reported questions and 5 questions related to the roommate/bed partner that are not included in the overall score. The 19 self-reported questions are divided into 7 components (respectively, subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime sleep dysfunction), and each component is scored on a scale of 0 to 3. The scores are then summed to form an overall scale of 0 to 21 points. The higher the score, the worse the sleep quality, and a PSQI greater than 5 indicates poor sleep quality.

    Time frame: 27 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Dec 2025, 8 months later.

Of 508 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 8 months is below that.

Counting every sponsor, half of 623 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2024
First posted
Aug 26, 2024
StartEst.
Apr 30, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2028
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06570629
Responsible party
Pedro Rodrigues Genta (Principal Investigator, University of Sao Paulo General Hospital) — Principal investigator
First posted
Aug 26, 2024
Start date
Apr 30, 2025 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 30, 2025

Study contacts

Pedro Genta
Contact
prgenta@gmail.com
551126625486
Pedro Genta
principal investigator · Study Principal Investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion